Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.32 - $0.62 $16,352 - $31,682
-51,100 Reduced 6.9%
689,870 $427,000
Q3 2023

Nov 14, 2023

BUY
$0.46 - $0.65 $34,638 - $48,945
75,300 Added 11.31%
740,970 $355,000
Q2 2023

Aug 14, 2023

BUY
$0.57 - $1.08 $138,510 - $262,440
243,000 Added 57.49%
665,670 $399,000
Q1 2023

May 15, 2023

BUY
$0.66 - $1.29 $125,862 - $246,003
190,700 Added 82.21%
422,670 $317,000
Q4 2022

Feb 14, 2023

BUY
$1.1 - $2.45 $210,870 - $469,665
191,700 Added 476.04%
231,970 $287,000
Q3 2022

Nov 14, 2022

SELL
$1.96 - $3.32 $133,476 - $226,092
-68,100 Reduced 62.84%
40,270 $83,000
Q2 2022

Aug 15, 2022

SELL
$2.27 - $4.86 $149,593 - $320,274
-65,900 Reduced 37.81%
108,370 $300,000
Q1 2022

May 16, 2022

SELL
$3.69 - $5.65 $608,481 - $931,685
-164,900 Reduced 48.62%
174,270 $762,000
Q4 2021

Feb 14, 2022

SELL
$5.37 - $7.07 $3.93 Million - $5.17 Million
-731,300 Reduced 68.32%
339,170 $1.87 Million
Q3 2021

Nov 15, 2021

SELL
$5.54 - $7.51 $1.01 Million - $1.37 Million
-183,000 Reduced 14.6%
1,070,470 $6.62 Million
Q2 2021

Aug 16, 2021

BUY
$7.78 - $11.4 $2.23 Million - $3.27 Million
286,600 Added 29.64%
1,253,470 $10.7 Million
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $1.13 Million - $1.87 Million
220,800 Added 29.6%
966,870 $7.65 Million
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $951,160 - $2.12 Million
301,000 Added 67.63%
746,070 $4.34 Million
Q3 2020

Nov 16, 2020

BUY
$3.26 - $4.73 $920,623 - $1.34 Million
282,400 Added 173.6%
445,070 $1.51 Million
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $241,108 - $706,538
152,600 Added 1515.39%
162,670 $751,000
Q1 2020

May 15, 2020

BUY
$1.44 - $3.02 $14,500 - $30,411
10,070 New
10,070 $16,000
Q3 2019

Nov 14, 2019

SELL
$2.67 - $3.65 $136,623 - $186,770
-51,170 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$2.6 - $4.21 $133,042 - $215,425
51,170 New
51,170 $147,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.